Education Sessions
Nanotechnology (206)
| 29 October 12.45-15.45 | Track: Innovation |
ISPE CEUs: 0.2
Nanotechnology promises a revolution in the field of medicine. Although there are a few nanoscale drug produts currently on the market, there is an enormous amount of research being done in this area. From transdermals and oral dosage products to biologics, nanotechnology could transform the future landscape of the pharmaceutical industry. The field is, however, still in its infancy. New processing technologies need to be developed and the debate over the safety and environmental impact of nanoparticles should be addressed. This session will provide an overview of the latest “nano” developments in pharma as well as where we are likely to be heading in the future.
How You Will Benefit
At the end of this session, participants will be able to:
- Understand the current state of nanotechnology in the pharmaceutical and biologics industry
- Identify the risks to employee safety
- Describe some of the new processes being developed and used to create drugs at the nanoscale
Who Should Attend
Professionals from process development, engineering, validation, environmental health and safety
ISPE Communities of Practice (COPs)
Active Pharmaceutical Ingredients (API), Biotechnology (Biotech), Containment, Commissioning and Qualification (C&Q), and Process/Product Development (PPD)
Session Leader
- Michael Denault, Principal, Denault Associates, USA
Session Speakers
- Michael Bolick, Founder, President and CEO, Selah Technologies, LLC, USA
- Kenneth Chomistek, Research Engineer, Microfluidics Corporation, USA
- T. Alan Hatton, Professor, Massachusetts Institute of Technology, USA